SAN FRANCISCO (GenomeWeb) – Natera said this week that sales of its noninvasive prenatal and carrier screening tests continue to grow, and although reimbursement progress for average-risk NIPT has been slow, it is ultimately inevitable in the US.
A trial upgrade to 360Dx Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try 360Dx Premium now.
Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.